Medicine and Dentistry
Patient
100%
Hepatocellular Carcinoma
65%
Inpatient
54%
Therapeutic Procedure
43%
Hepatitis C
41%
Infection
38%
Chronic Hepatitis C
35%
Liver Cirrhosis
33%
Antivirus Agent
28%
Hepatitis C Virus
27%
Genotype
23%
Antiviral Therapy
22%
Screening
21%
Hepatitis B Virus
21%
Hepatitis B Antigen
19%
Hepatitis B
17%
Sorafenib
16%
Platelet
16%
Sofosbuvir
15%
Prevalence
15%
Hospital
14%
Combination Therapy
12%
Serum
12%
Fibrosis
11%
Experience
11%
Somatomedin C Receptor
11%
Survival
11%
Liver Fibrosis
11%
Neoplasm
11%
Ribavirin
11%
Stomach Cancer
10%
Antigen
10%
Chronic Viral Hepatitis
10%
Inflammation
10%
Rheumatoid Factor
10%
Glomerular Filtration Rate
10%
Kidney Function
10%
Glecaprevir Plus Pibrentasvir
10%
Diagnosis
10%
Incidence
10%
Velpatasvir
10%
Hazard Ratio
10%
Cholangiocarcinoma
9%
Analysis
8%
Body Mass Index
7%
Health
7%
Virus RNA
7%
Surgery
7%
Age
7%
Chronic Hepatitis B
6%
Nursing and Health Professions
Hepatitis C
66%
Patient
41%
Chronic Hepatitis C
36%
Infection
29%
Antiviral Therapy
25%
Liver Cirrhosis
23%
Sofosbuvir
21%
Glecaprevir Plus Pibrentasvir
21%
Screening
17%
Hepatitis B
17%
Hepatitis B Surface Antigen
16%
Velpatasvir
16%
Liver Cell Carcinoma
16%
Combination Therapy
13%
Antivirus Agent
12%
Analysis
12%
Ribavirin
12%
Prevalence
11%
Adult
11%
Estimated Glomerular Filtration Rate
11%
Virus Load
11%
Fibrosis
11%
Antigen
10%
Ledipasvir Plus Sofosbuvir
10%
Rheumatoid Factor
10%
Health Status
8%
Side Effect
8%
Incidence
8%
Confidence Interval
7%
Sustained Virologic Response
7%
Chronic Hepatitis B
6%
Platelet Count
6%
Hepatitis
6%
Virus Infection
6%
Adverse Event
6%
Odds Ratio
6%
Liver Cancer
6%
Hospital
6%
Predictive Value
5%
Virus RNA
5%
Liver Fibrosis
5%
Health Literacy
5%
Tenofovir
5%
Counseling
5%
Anemia
5%
Measurement
5%
Blood Test
5%
Nursing
5%
Occupation (Patient Social Context)
5%
Prospective Cohort Study
5%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
42%
Hepatitis C
40%
Glecaprevir Plus Pibrentasvir
38%
Liver Cirrhosis
31%
Antivirus Agent
26%
Sofosbuvir
26%
Hepatitis C Virus
25%
Infection
23%
Sorafenib
21%
Chronic Hepatitis C
21%
Velpatasvir
21%
Stomach Cancer
16%
Hepatitis B Virus
14%
Malignant Neoplasm
14%
Hepatitis B Surface Antigen
12%
Prognosis
12%
Hepatitis B
12%
Somatomedin C Receptor
12%
Adverse Event
11%
Fibrosis
9%
Incidence
9%
Octamer Transcription Factor 4
8%
Glecaprevir Plus Pibrentasvir
8%
Hepatitis C
8%
Drug Resistance
8%
Antigen
7%
Ribavirin
7%
Chronic Hepatitis B
7%
Pruritus
6%
Protein
6%
Inflammation
6%
Antiviral Therapy
6%
DNA (Cytosine 5) Methyltransferase 1
6%
Metastasis
5%
Virus
5%
Apoptosis
5%
Liver Fibrosis
5%
Stromal Cell Derived Factor 1
5%
Virus Infection
5%
DNA Methyltransferase
5%
Ledipasvir Plus Sofosbuvir
5%
Resveratrol
5%
Mitogen Activated Protein Kinase P38
5%
Upper Gastrointestinal Bleeding
5%
Tenofovir
5%
Entecavir
5%
Interleukin 6
5%
Bupivacaine
5%
Somatomedin
5%
Niclosamide
5%